非小细胞肺癌的 EGFR-TKI 新辅助疗法

IF 11.3 1区化学 Q1 CHEMISTRY, PHYSICAL ACS Catalysis Pub Date : 2024-03-27 DOI:10.1016/j.ctrv.2024.102724

Christopher Grant , Misako Nagasaka

{"title":"非小细胞肺癌的 EGFR-TKI 新辅助疗法","authors":"Christopher Grant , Misako Nagasaka","doi":"10.1016/j.ctrv.2024.102724","DOIUrl":null,"url":null,"abstract":"<div><p>Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with <em>EGFR</em> and <em>ALK</em> alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with <em>EGFR-TKI</em> monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials’ potential benefits, challenges, and future directions in the field.</p></div>","PeriodicalId":9,"journal":{"name":"ACS Catalysis ","volume":null,"pages":null},"PeriodicalIF":11.3000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000513/pdfft?md5=a916c4b1247f0df2d57685d15c548e76&pid=1-s2.0-S0305737224000513-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer\",\"authors\":\"Christopher Grant , Misako Nagasaka\",\"doi\":\"10.1016/j.ctrv.2024.102724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with <em>EGFR</em> and <em>ALK</em> alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with <em>EGFR-TKI</em> monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials’ potential benefits, challenges, and future directions in the field.</p></div>\",\"PeriodicalId\":9,\"journal\":{\"name\":\"ACS Catalysis \",\"volume\":null,\"pages\":null},\"PeriodicalIF\":11.3000,\"publicationDate\":\"2024-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0305737224000513/pdfft?md5=a916c4b1247f0df2d57685d15c548e76&pid=1-s2.0-S0305737224000513-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Catalysis \",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0305737224000513\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Catalysis ","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737224000513","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

摘要

非小细胞肺癌（NSCLC）I-III 期主要采用手术和免疫化疗联合疗法进行治疗。这些研究大多排除了表皮生长因子受体（EGFR）和ALK改变的患者。有几项已完成和正在进行的试验评估了 EGFR-TKI 单药、化疗联合疗法以及免疫疗法联合疗法的新辅助治疗。在此，我们回顾了已完成的临床试验，并讨论了目前正在进行的试验的潜在益处、挑战以及该领域的未来发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials’ potential benefits, challenges, and future directions in the field.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Catalysis CHEMISTRY, PHYSICAL-

CiteScore

20.80

自引率

6.20%

发文量

1253

审稿时长

1.5 months

期刊介绍： ACS Catalysis is an esteemed journal that publishes original research in the fields of heterogeneous catalysis, molecular catalysis, and biocatalysis. It offers broad coverage across diverse areas such as life sciences, organometallics and synthesis, photochemistry and electrochemistry, drug discovery and synthesis, materials science, environmental protection, polymer discovery and synthesis, and energy and fuels. The scope of the journal is to showcase innovative work in various aspects of catalysis. This includes new reactions and novel synthetic approaches utilizing known catalysts, the discovery or modification of new catalysts, elucidation of catalytic mechanisms through cutting-edge investigations, practical enhancements of existing processes, as well as conceptual advances in the field. Contributions to ACS Catalysis can encompass both experimental and theoretical research focused on catalytic molecules, macromolecules, and materials that exhibit catalytic turnover.